Your opportunity to shape tomorrow's medicine.

Financial goals

Currently, Ohmline development is financially sustained by 500,000 € from public funding programs of the Spanish and Madrid Local Governments. A priority goal of Lifesome is to secure private funding for completion of the pre-clinical development of Ohmline. Budget for GLP toxicology studies has been estimated in around 1,500,000 €: Lifesome aims to secure 1 million € from private capital businesses and an additional half million € in loans from Spanish Industry Ministry ENISA program. Lifesome Therapeutics aims to progress Ohmline development as an oncology therapeutic agent to Phase I clinical studies completion being in an advantageous position for attracting a broad base of shareholders. Upon the completion of Phase I clinical trial by 2027, proving Ohmline safety, our technology will be ready to be licensed (non-exclusively) to pharma companies, as a next-generation drug delivery system that can synergistically improve the effectsof the transported drug. Maintaining the company independence is key to achieve our vision of introducing the next generation of therapeutic nanocarriers across the whole pharma industry. Non-exclusive licensing of our products to different companies will allow a wide array of anticancer drugs to be delivered more efficiently in a cost-effective fashion.

Preliminary briefing meeting is being scheduled with EMA’s Innovation Task Force for getting experts opinion on the best strategy to achieve an accelerated pre-clinical evaluation and clinical studies authorization. However, interaction with others regulatory authorities (e.g., FDA) is not ruled out.

Team & facilities

All current employees are PhD researchers (6), both young and experienced staff from academy and industry. The company current facilities are based at the deep tech business incubator area Madrid Science Park, including office and lab space. Also, an agreement has been signed with Fundación Jiménez Díaz Hospital (Madrid) and Centro Nacional de Biotecnologia, CNB (Madrid) to perform preclinical studies at their cell culture and animal facilities.